Edwards Lifesciences Corp (EW) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has...
Edwards Lifesciences Corp's revenue increased 11.5% year over year, from $5.44B to $6.07B.
Net income decreased 74.3% over the same period, from $4.17B to $1.07B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 105% in total.
Total debt remained relatively stable at $598.3M.
The debt-to-equity ratio stands at 0.06, indicating a conservative leverage profile.
Operating cash flow grew 194.2% to $1.60B.
Edwards Lifesciences Corp maintains a healthy net profit margin of 17.7%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $1.32B+16.4% | $3.07B | $1.08B | $345.9M | $351.8M | $12.97B | $597.5M | $9.55B |
| Q4 FY2024 | $1.39B+4.9% | $385.6M | $1.09B | $312.6M | $-127.5M | $13.06B | $597.7M | $10.00B |
| Q1 FY2025 | $1.41B+1.9% | $358.0M | $1.11B | $394.8M | $280.4M | $13.02B | $597.8M | $10.13B |
| Q2 FY2025 | $1.53B+8.5% | $333.2M | $1.19B | $411.2M | $290.2M | $13.49B | $598.0M | $10.55B |
| Q3 FY2025 | $1.55B+1.4% | $291.1M | $1.21B | $307.1M | $573.7M | $13.27B | $598.2M | $10.21B |
| Q4 FY2025 | $1.57B+1.1% | $91.2M | $1.23B | $151.1M | $450.9M | $13.70B | $598.3M | $10.34B |
| Q1 FY2026 | $1.65B+5.0% | $380.7M | $1.29B | $477.6M | $43.8M | $13.32B | $702.9M | $10.33B |
| Q2 FY2026 | $1.74B+5.6% | $241.9M | $1.35B | $513.2M | $651.9M | $13.87B | $704.4M | $10.72B |
Balance Sheet Summary (Q2 FY2026)
Edwards Lifesciences Corp (EW) Financial Statements & Revenue History
Edwards Lifesciences Corp (EW) is a US-listed stock operating in the Healthcare sector, specifically the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry trading at $86.60 with a market capitalization of $50. This page provides 42 historical financial statements for Edwards Lifesciences Corp, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Edwards Lifesciences Corp reported revenue of $6.1 billion, representing 11.5% year-over-year growth. The net profit margin of 17.7% reflects strong profitability. The debt-to-equity ratio of 0.06 shows conservative leverage.
EW Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Edwards Lifesciences Corp's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether EW is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track EW's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Edwards Lifesciences Corp converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of EW's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use EW Financial Data
Investors use Edwards Lifesciences Corp's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare EW's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how EW's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View EW's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Edwards Lifesciences Corp's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.EW trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.